First brazilian consensus of advanced prostate cancer: recommendations for clinical practice

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP SASSE, Andre Deeke
WIERMANN, Evanius Garcia
SCHUTZ, Fabio A.
MALUF, Fernando Cotait
MORBECK, Igor Alexandre Protzner
CERCI, Juliano J.
LIMA, Volney Soares
CAMPOS, Franz Santos de
CARVALHAL, Gustavo Franco
CEZAR, Leandro Casemiro
DALL'OGLIO, Marcos Francisco FMUSP-HC
SADI, Marcus Vinicius
REIS, Rodolfo Borges dos
NOGUEIRA, Lucas 2017
dc.identifier.citation INTERNATIONAL BRAZ J UROL, v.43, n.3, p.407-415, 2017
dc.identifier.issn 1677-5538
dc.description.abstract Introduction: Prostate cancer still represents a major cause of morbidity, and still about 20% of men with the disease are diagnosed or will progress to the advanced stage without the possibility of curative treatment. Despite the recent advances in scientific and technological knowledge and the availability of new therapies, there is still considerable heterogeneity in the therapeutic approaches for metastatic prostate cancer. Objectives: This article presents a summary of the I Brazilian Consensus on Advanced Prostate Cancer, conducted by the Brazilian Society of Urology and Brazilian Society of Clinical Oncology. Materials and Methods: Experts were selected by the medical societies involved. Forty issues regarding controversial issues in advanced disease were previously elaborated. The panel met for consensus, with a threshold established for 2/3 of the participants. Results and Conclusions: The treatment of advanced prostate cancer is complex, due to the existence of a large number of therapies, with different response profiles and toxicities. The panel addressed recommendations on preferred choice of therapies, indicators that would justify their change, and indicated some strategies for better sequencing of treatment in order to maximize the potential for disease control with the available therapeutic arsenal. The lack of consensus on some topics clearly indicates the absence of strong evidence for some decisions.
dc.description.sponsorship · Brazilian Society of Clinical Oncology
· Brazilian Society of Urology
dc.language.iso eng
dc.relation.ispartof International Braz J Urol
dc.rights openAccess
dc.subject Prostatic Neoplasms; Practice Guideline [Publication Type]; Diagnosis
dc.subject.other placebo-controlled phase-3; abiraterone acetate; survival analysis; plus prednisone; double-blind; open-label; enzalutamide; chemotherapy; docetaxel; mitoxantrone
dc.title First brazilian consensus of advanced prostate cancer: recommendations for clinical practice
dc.type article
dc.rights.holder Copyright BRAZILIAN SOC UROL LIM/43
dc.identifier.doi 10.1590/S1677-5538.IBJU.2016.0490
dc.identifier.pmid 28199075
dc.type.category original article
dc.type.version publishedVersion BASTOS, Diogo Assed:HC:ICESP COURA FILHO, George:HC:ICESP DALL'OGLIO, Marcos Francisco:FM:MCG · SASSE, Andre Deeke:Univ Estadual Campinas, Clin Med, Campinas, SP, Brazil
· WIERMANN, Evanius Garcia:Soc Brasileira Oncol Clin, Belo Horizonte, MG, Brazil
· HERCHENHORN, Daniel:INCA, Inst Nacl Canc, Rio De Janeiro, RJ, Brazil
· SCHUTZ, Fabio A.:Beneficiencia Portuguesa Sao Paulo, Sao Paulo, SP, Brazil
· MALUF, Fernando Cotait:Beneficiencia Portuguesa Sao Paulo, Sao Paulo, SP, Brazil; Hosp Israelita Albert Einstein, Dept Oncol, Sao Paulo, SP, Brazil
· MORBECK, Igor Alexandre Protzner:Univ Catolica Brasilia, Taguatinga, DF, Brazil
· CERCI, Juliano J.:Univ Sao Paulo, Sao Paulo, SP, Brazil
· SMALETZ, Oren:Hosp Israelita Albert Einstein, Dept Oncol, Sao Paulo, SP, Brazil
· LIMA, Volney Soares:Oncoctr, Belo Horizonte, MG, Brazil
· ADAMY JR., Ari:Hosp Santa Casa, Dept Urol, Curitiba, Parana, Brazil
· CAMPOS, Franz Santos de:INCA, Inst Nacl Canc, Rio De Janeiro, RJ, Brazil
· CARVALHAL, Gustavo Franco:Pontificia Univ Catolica Rio Grande do Sul, Dept Cirurgia, Porto Alegre, RS, Brazil; Pontificia Univ Catolica Rio Grande do Sul, Dept Urol, Porto Alegre, RS, Brazil
· CEZAR, Leandro Casemiro:Hosp Fed Cardoso Fontes, Rio De Janeiro, RJ, Brazil
· SADI, Marcus Vinicius:Univ Fed Sao Paulo, Sao Paulo, SP, Brazil
· REIS, Rodolfo Borges dos:Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil
· NOGUEIRA, Lucas:Univ Fed Minas Gerais, Hosp Clin, Dept Urol, Belo Horizonte, MG, Brazil 2-s2.0-85020167489 WOS:000403885400006 SCIELO:S1677-55382017000300407 RIO DE JANEIRO BRAZIL
hcfmusp.relation.reference · Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815
· Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
· Carneiro A, 2015, WORLD J UROL, V33, P1281, DOI 10.1007/s00345-014-1439-6
· Dalesio O, 2000, LANCET, V355, P1491
· de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
· Finlay OG, 2005, LANCET ONCOL, V6, P392
· Fizazi K, 2012, LANCET ONCOL, V13, pE464
· Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0
· Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6
· Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257
· Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0
· James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5
· MILHOLLAND AV, 1973, NEW ENGL J MED, V288, P1272, DOI 10.1056/NEJM197306142882405
· Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
· Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7
· Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
· Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
· Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
· [Anonymous], 2016, ESTIMATIVAS 2016 INC
dc.description.index MEDLINE
dc.identifier.eissn 1677-6119
hcfmusp.citation.scopus 4
hcfmusp.citation.wos 4 Brasil

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account